Wechselwirkungen · Emselex
Emselex 7.5 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-113070 · Präparat HOS-093835
CYP3A4 inhibitors Darifenacin should not be used together with potent CYP3A4 inhibitors (see section 4.3) such as protease inhibitors (e.g. ritonavir), ketoconazole and itraconazole. Potent P-glycoprotein inhibitors such as ciclosporin and verapamil should also be avoided. Co-administration of darifenacin 7.5 mg with the potent CYP3A4 inhibitor ketoconazole 400 mg resulted in a 5-fold increase in steady-state darifenacin AUC. In subjects who are poor metabolisers, darifenacin exposure increased approximately 10-fold. Due to a greater contribution of CYP3A4 after higher darifenacin doses, the magnitude of the effect is expected to be even more pronounced when combining ketoconazole with darifenacin 15 mg.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-15T12:10:00Z · SHA-256 de750767f67ad57bdc05ce4c855b9a1fcf428d24652a741d2de5aacfc4e7ad1c · Passage 43f13b430a95a055a1a68c4e8fed7001b4439d8cbedc47269d174d756918ce66 · Zeichen 692–1405 im Abschnitt